Establishment of NOD-Pdcd1-/- Mice As an Efficient Animal Model of Type I Diabetes

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2005 Aug 10

PMID 16087865

Citations 229

Authors

Jian Wang

Taku Yoshida

Fumio Nakaki

Hiroshi Hiai

Taku Okazaki

Tasuku Honjo

Affiliations

Soon will be listed here.

Abstract

Mice deficient in programmed cell death 1 (PD-1, Pdcd1), an immunoinhibitory receptor belonging to the CD28/cytotoxic T lymphocyte-associated antigen-4 family, spontaneously develop lupus-like autoimmune disease and autoimmune dilated cardiomyopathy on C57BL/6 and BALB/c backgrounds, respectively. However, how PD-1 deficiency induces different forms of autoimmune diseases on these two strains was unknown. Here, we report that PD-1 deficiency specifically accelerates the onset and frequency of type I diabetes in NOD (nonobese diabetic) mice, with strong T helper 1 polarization of T cells infiltrating into islets. These results suggest that PD-1 deficiency accelerates autoimmune predisposition of the background strain, leading to the induction of different forms of autoimmune diseases depending on the genetic background of the strain. Using NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes, we screened diabetes-susceptible loci by genetic linkage analysis. The diabetic incidence of NOD-Pdcd1-/- mice was controlled by five genetic loci, including three known recessive loci [Idd (insulin-dependent diabetes) 1, Idd17, and Idd20] and two previously unidentified dominant loci [Iddp (Idd under PD-1 deficiency) 1 and Iddp2].

Citing Articles

Circulating T Cell Subsets in Type 1 Diabetes.

Ferreira-Hermosillo A, Santana-Sanchez P, Vaquero-Garcia R, Garcia-Saenz M, Castro-Rios A, Chavez-Rueda A Cells. 2025; 14(1.

PMID: 39791749 PMC: 11719944. DOI: 10.3390/cells14010048.

The harmful effect of ankylosing spondylitis on diabetes mellitus: new evidence from the Mendelian randomization analysis.

Ren Z, He L, Wang J, Shu L, Li C, Ma Y Front Endocrinol (Lausanne). 2024; 15():1369466.

PMID: 39649224 PMC: 11624504. DOI: 10.3389/fendo.2024.1369466.

Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus.

Kani E, Karaviti E, Karaviti D, Gerontiti E, Paschou I, Saltiki K Endocrine. 2024; 87(3):875-890.

PMID: 39316333 DOI: 10.1007/s12020-024-04050-5.

Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.

Pavelescu L, Enache R, Rosu O, Profir M, Cretoiu S, Gaspar B Int J Mol Sci. 2024; 25(17).

PMID: 39273605 PMC: 11395316. DOI: 10.3390/ijms25179659.

Immune checkpoint inhibitors in infectious disease.

King H, Lewin S Immunol Rev. 2024; 328(1):350-371.

PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.

References

Adorini L, Gregori S, Harrison L . Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med. 2002; 8(1):31-8. DOI: 10.1016/s1471-4914(01)02193-1. View

Deruytter N, Boulard O, Garchon H . Mapping non-class II H2-linked loci for type 1 diabetes in nonobese diabetic mice. Diabetes. 2004; 53(12):3323-7. DOI: 10.2337/diabetes.53.12.3323. View

Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K . Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol. 2002; 3(5):443-50. DOI: 10.1038/ni793. View

Van Blokland S, Versnel M . Pathogenesis of Sjögren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol. 2002; 103(2):111-24. DOI: 10.1006/clim.2002.5189. View

Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J . Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003; 9(12):1477-83. DOI: 10.1038/nm955. View

Subudhi S, Zhou P, Yerian L, Chin R, Lo J, Anders R . Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest. 2004; 113(5):694-700. PMC: 351315. DOI: 10.1172/JCI19210. View

Latchman Y, Liang S, Wu Y, Chernova T, Sobel R, Klemm M . PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004; 101(29):10691-6. PMC: 489996. DOI: 10.1073/pnas.0307252101. View

Kendall P, Woodward E, Hulbert C, Thomas J . Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur J Immunol. 2004; 34(9):2387-95. DOI: 10.1002/eji.200324744. View

Shim G, Warner M, Kim H, Andersson S, Liu L, Ekman J . Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A. 2004; 101(34):12628-33. PMC: 515108. DOI: 10.1073/pnas.0405099101. View

10.

Nguyen C, Limaye N, Wakeland E . Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res. 2002; 4 Suppl 3:S255-63. PMC: 3240158. DOI: 10.1186/ar583. View

11.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View

12.

Okazaki T, Iwai Y, Honjo T . New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 2002; 14(6):779-82. DOI: 10.1016/s0952-7915(02)00398-9. View

13.

Morahan G, Morel L . Genetics of autoimmune diseases in humans and in animal models. Curr Opin Immunol. 2002; 14(6):803-11. DOI: 10.1016/s0952-7915(02)00401-6. View

14.

Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T . PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003; 198(1):39-50. PMC: 2196084. DOI: 10.1084/jem.20022235. View

15.

Ansari M, Salama A, Chitnis T, Smith R, Yagita H, Akiba H . The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198(1):63-9. PMC: 2196083. DOI: 10.1084/jem.20022125. View

16.

Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G . Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33(10):2706-16. DOI: 10.1002/eji.200324228. View

17.

Gregori S, Giarratana N, Smiroldo S, Adorini L . Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003; 171(8):4040-7. DOI: 10.4049/jimmunol.171.8.4040. View

18.

Yang Y, Santamaria P . Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice. Diabetologia. 2003; 46(11):1447-64. DOI: 10.1007/s00125-003-1218-1. View

19.

Griffiths M, Encinas J, Remmers E, Kuchroo V, Wilder R . Mapping autoimmunity genes. Curr Opin Immunol. 2000; 11(6):689-700. DOI: 10.1016/s0952-7915(99)00038-2. View

20.

Wakeland E, Wandstrat A, Liu K, Morel L . Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol. 2000; 11(6):701-7. DOI: 10.1016/s0952-7915(99)00039-4. View